Invion

Invion Receivables/Revenue

The Receivables to Revenue Ratio of Invion (IVX.AX) as of Oct 23, 2026 is 4.25 %. In the previous year, Receivables to Revenue Ratio was 0.47 % — a change of 800.88% (higher).

Receivables/Revenue

4.25 %

YoY

800.88%

Last updated:

Receivables to Revenue Ratio of Invion is 2022 4.25 % . Receivables to Revenue Ratio of Invion was 2021 0.47 % . It decreases by 800.88% higher compared to the previous year.

The Invion Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2016
465.49 AUD
Jan 1, 2018
12.44 AUD
Jan 1, 2019
0.74 AUD
Jan 1, 2020
7.11 AUD
Jan 1, 2021
0.47 AUD
Jan 1, 2022
4.25 AUD
The Invion Receivables/Revenue history
YEARReceivables/RevenueYoY
4.25 %+800.88%
0.47 %-93.36%
7.11 %+858.78%
0.74 %-94.04%
12.44 %-97.33%
465.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Receivables to Revenue Ratio of Invion is 4.25 % in 2022.

Receivables to Revenue Ratio of Invion changed from 0.47 % to 4.25 %, representing a 800.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Invion

All Key Metrics — Invion